Wiskott-Aldrich syndrome is a hematological disorder with impaired function and number of platelets and lymphocytes. The typical symptoms comprise eczema, thrombopenia and recurrent infections. Mutations in the WAS gene at XP11.22, primarily expressed in hematopoietic cells, have been shown to cause this X-linked immunodeficiency.
1,2
Transplantation of allogeneic stem cells is the only curative approach to date. Thus, for patients who lack an identical sibling or unrelated donor, transplants from mismatched related (haploidentical) donors are increasingly used. However, graft failure, EBV-LPD and severe viral infections remain major obstacles, especially when direct T-cell depletion methods are used. 1, 3, 4 Moreover, after successful transplantation, a high rate of mixed hematopoietic chimeras (30-50% of patients) were observed in lymphocytes, monocytes and megakaryocytes, sometimes associated with persistent thrombocytopenia.
4-6
Here we present the case of a 12-year-old boy with sustained low platelet counts after transplantation of unmanipulated bone marrow from his nonidentical father, and show that his platelets were normalized by a stem cell boost, consisting of CD133 þ selected progenitors.
The diagnosis of WAS was ascertained in our patient at 9 months of age (eczema, bloody diarrhea, decreased number and size of platelets (10 000-40 000/ml, 5.1 fl), reduced percentage and mitogenic response of T cells, decreased levels of IgM and elevated IgA). During the succeeding year, he suffered from skin abscesses with Staphylococcus aureus, followed by septicemia and osteomyelitis, and developed an immune vasculitis with congestive heart failure. Since the patient lacked a HLA-identical donor, we decided to use his one antigen (HLA-A in HvGdirection)-mismatched father. At 2 years of age in 1993, the boy received 2.2 Â 10 8 MNC/kg of unmanipulated bone marrow. The conditioning regimen included busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg); GvHD prophylaxis was provided by cyclosporine A (5 mg/ kg) and methotrexate (3 Â 10 mg/m 2 ). Acute GvHD (skin) was successfully treated with prednisone (4 mg/kg); no chronic GvHD occurred. Neutrophil recovery was reached within 18 days, and, at day 100, complete donor chimerism was established. His immunodeficiency resolved, whereas thrombocytopenia persisted ( Figure 1 ). In parallel, a mixed hematopoietic chimerism was observed with increasing autologous signals (maximum 80% of recipient origin in the myeloid fraction), while T cells and B cells were predominantly of donor origin. Chimerism was assessed by PCR in peripheral blood samples, as described previously. 7, 8 At 12 years of age, the patient asked for additional treatment options because of a persistent bleeding tendency. Progress in the intervening years in graft processing and manipulation has allowed the selection of megadoses of highly purified peripheral progenitor cells, which in turn allow allogeneic transplantation even in three antigenmismatch donor-recipient pairs without the risk of severe GVHD. Therefore, in 2003, we decided to administer a boost of positively selected stem cells without conditioning. For this purpose, the father underwent one large volume leukapheresis after 5 days of G-CSF mobilization (10 mg/kg s.c.). Cells were selected with anti-CD133-coated microbeads using the CLINIMACS device (Miltenyi-Biotec). The enriched graft consisted predominantly of CD133 þ /CD34 þ double-positive cells (purity 98.7% CD133 þ ) with 0.09% contaminating CD3 þ cells and 0.76% CD19 þ cells. Cell viability was 495%. Thus, the patient received a total of 8.3 Â 10 6 /kg freshly isolated stem cells with only 8000 residual T cells/kg. Although immune suppression was avoided completely, no signs of GvHD occurred. Starting 3 weeks after the boost, platelet counts increased and remained 4100 000 since then (7 months up to now). Moreover, chimerism analysis showed decreasing autologous signals.
Persistent post transplant thrombocytopenia has been reported in some patients with Wiskott-Aldrich syndrome. The reasons are not fully understood. However, in some cases, low platelet counts were associated with mixed chimerism in myelopoiesis exhibiting a high percentage of recipient cells.
6 In our patient, T cells were mainly of donor origin, whereas myelopoiesis was mainly of recipient origin. We suppose that these findings may account for his immunocompetence and thrombocytopenia, respectively.
An additional dose of purified CD133 þ selected peripheral progenitors (stem cell boost) improved megakaryopoiesis markedly and reduced mixed chimerism without any immunoablative therapy. Estimating 1% CD133 þ cells in bone marrow, the boost comprised approximately four times more CD133 þ progenitors than the original unmanipulated graft. We hypothesize that both the high cell dose and the survival advantage of normal precursors bearing no WAS gene mutation helped to restrain the recipient's myelopoiesis. Although the number of residual T cells in the boost was extremely low and therefore no GvHD occurred, we cannot definitely rule out that these cells also influenced the chimerism status.
We used CD133 þ selected cells, since this subset has been shown to contain primitive cells that are able to efficiently produce all categories of megakaryocyte progenitors in vitro.
9 In addition, preliminary data of our institution suggested favorable platelet recovery in patients with CD133 þ selected grafts. 10 It is possible that the results presented here may in part be due to this selection method. However, we cannot exclude that the same results would have been obtained also with CD34 þ selection, which is the more established method to date.
Thus, boosts with high doses of positive selected stem cells may help to increase hematopoiesis without the risk of inducing GvHD or EBV-LPD in patients in whom transplant tolerance has been already achieved.
11 In particular, this approach may contribute to improve mismatched related transplantations for Wiskott-Aldrich syndrome. 
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